| By Lonza - Basel, Switzerland |
| Thursday, 25 September 2008 |
 |
Lonza and Crucell N.V. entered into a co-exclusive global manufacturing, sales and distribution agreement related to the PERMEXCIS™ cell culture medium developed by Crucell for PER.C6® cells. Under this agreement Lonza will manufacture, market and sell the medium on a global basis. |
|
Financial details of the agreement were not disclosed.
The PERMEXCIS™ medium is a chemically defined cell culture medium that does not contain human- or animal-derived components. PERMEXCIS™ medium was developed for the cultivation of PER.C6® cells and has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines. This novel medium has proven, in a comparison study performed by Crucell, to provide higher viral vaccine product yields in PER.C6®-based manufacturing processes than some of the currently marketed media for PER.C6® cells.
“Lonza is pleased to enter into this agreement with Crucell N.V. Lonza is a leader in cell culture technology and media manufacturing , with a broad range of specialized media for all the major cell lines used in the biopharmaceutical industry.
The new PER.C6® medium is a complementary addition to the Lonza Serum Free Medium product range”, said Roel Gordijn, Global Sales and Marketing Director for Media in the |
|
|
Bioscience business of Lonza.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically.
Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion.
Further information can be found at www.lonza.com.
About Crucell
Crucell N.V. is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and
|
|
antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza.
Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.
The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry.
Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over 1000 people.
For more information, please visit www.crucell.com.
_____________________________
Want to read more?
_____________________________
Pierre FABRE donates the majority equity interest in his company
E.T. Horn to Represent the Dr. Paul Lohmann Company
Informex Opens Registration to Informex USA 2009
|
|
|
